Status of hypertension screening in the Korea National General Health Screening Program: a questionnaire survey on 210 screening centers in two metropolitan areas

Seung Won Lee¹,², Hae-Young Lee³, Sang Hyun Ihm⁴, Sung Ha Park⁵, Tae Hyun Kim⁶ and Hyeon Chang Kim¹,²*

Abstract

Background: The purpose of this survey was to evaluate the performance of hypertension screening in medical institutions conducting the national general health screening program of the Republic of Korea.

Methods: We contacted 700 medical institutions of Seoul and Incheon areas which performed the national general health screening program in 2016, and 210 of them completed telephone survey. The questions asked in the survey include equipment, environment, personnel and quality control procedures for blood pressure (BP) measurement, and interpretation of the measurements.

Results: A majority of the responding screening centers used oscilloscope sphygmomanometers (51.9%), had only one-sized cuff (65.2%), and measured BP in open space (54.3%). BP levels were measured mainly by nurses (62.0%) and doctors (25.0%), after a 1 to 10 minutes (84.9%) of resting period. A 75.2% of screening centers regularly calibrated sphygmomanometers, 81.4% had a manual for BP measurement, and 59.0% had a training program. A 80.0% of respondents answered that they used averages of multiple BP measurements to determine an individual’s BP level, and 82.9% answered that criteria for hypertension was systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg. If a screening finds an individual with hypertension, 82.9% of centers recommend revisiting for a second BP measurement rather than start medication immediately.

Conclusion: In most medical institutions performing general health screening program, certified medical personnel measure BP and interpret the results according to established protocols. However, there is room for improvement in the equipment, environment and quality control procedures for BP measurement.

Keywords: Hypertension, Blood pressure, Screening, Sphygmomanometer, Quality control

Background

Hypertension, the most important modifiable risk factor for cardiovascular diseases, is a major health burden and the leading cause of death in the worldwide [1–4]. Previous studies reported that the reduction of highly or moderately elevated BP levels results in a decrease in stroke and myocardial infarction rates [5, 6]. Every 10 mmHg increase in systolic blood pressure (BP) or diastolic BP is estimated to double the risk of death from ischemic heart disease and stroke [7].

In Korea, diseases of circulatory system including coronary heart disease and stroke accounted for 22% of the entire death in 2015 [8]. The number of people who visited the hospital for chronic diseases in 2015 was 14.39 million, with the highest number of hypertension (5.71 million) among them in Korea. Prevalence of hypertension was estimated to about 35.1% for male, and 29.1%
for female among Korean adults aged 30 years and above in 2015 [9]. According to the Korean Nation Health Survey in 2001, the age-adjusted prevalence of hypertension was 22.9% (26.9% in men and 20.5% in women) [10]. Especially, hypertension is a common disease among Korean elderly population aged 65 years or older considering that its prevalence increased between 2007 and 2011 from 49.3% to 58.4% in men and from 61.8% to 68.9% in women [11]. Total medical cost for hypertension was estimated to 2850 billion Korean won (KRW) which accounts for 13.4% of medical cost due to all chronic disorders [12]. This means that controlling hypertension is crucial to reducing the overall burden of disease in society and improving quality of life. Therefore, many countries carry out national health screening and emphasize the importance of measuring BP. The benefits of screening for hypertension are well established [13–15]. However, although hypertension screening is a very important for preventing of hypertension, there have been few studies on hypertension screening in Korea. Thus, we evaluated the performance of hypertension screening and interpretation of BP measurements in medical institutions performing the national general health screening program of the Republic of Korea.

Methods

This descriptive survey aims to collect information on protocol of BP measurement, setting condition of measurement place, diagnosis of hypertension, and criteria of medicine prescription. First, we made a multiple-choice questionnaire to conduct a survey using telephone. The survey was conducted by trained telephone interviewers for February and March of 2016. A total of 5435 medical institutions, including clinics, general hospital, long-term care hospital, hospitals, and health center, were able to conduct surveys in 2016. We contacted 700 medical institutions of Seoul and Incheon areas which performed the national general health screening program in 2016, and 210 of them completed telephone survey. We made questionnaire items based on hypertension screening protocol of Korea National Health Insurance [16] with reviewing seventh and eighth report of the Joint National Committee (JNC) [17, 18], and 2013 guidelines on hypertension of the European Society of Hypertension and the European Society of Cardiology (ESH/ESC) [19]. According to protocol for BP measurement in national health screening program, all examinees had rested for at least 5 min in a seated position prior to first measurement. BP should be measured by the auscultation method using a stethoscope or using an oscillometric automatic sphygmomanometer in a quiet environment. The calibration of devices should be checked day-to-day. A cuff with an appropriately sized bladder should be used. The standard bladder for adults is 12 cm wide and 26 cm long. The use of a bladder with a width of at least 40% of the circumference of the arm and a length of 80% to 100% of the circumference of the arm is recommended. Examinees are recommended to avoid smoking, alcohol, or caffeine before measurement. We made the questionnaire items reflecting these protocols.

Results

A 210 responding medical institutions includes 154 clinics, 38 hospitals, 15 general hospitals, 2 long-term care hospitals, and 1 health check-up center (Table 1). Most screening centers (51.9%) used oscilloscope sphygmomanometer to measure BP, and the percentage of medical institutions using only mercury sphygmomanometers was 44%. A 75.2% of medical institutions regularly check whether sphygmomanometers operate normally. A 65.2% of the medical institutions had only one cuff size, and 40.5% said they use a thermometer. A majority of the screening centers used open space (54.3%) to measure BP and 28.6% of the medical institutions used an independent place for BP measurement only. People who measure BP were mainly the nurse (62%) and the doctor (25%).

BP was measured twice or more in 59.5% of medical institutions, and 35.2% of medical institution measured BP only one time (Table 2). A 18.6% of the medical institutions did not have manual to measure BP and 40.5% did not perform the BP measurement training. A majority of the medical institutions (93.8%) did not measure the arm circumference to select the appropriate cuff size. A 94.8% of medical institutions said they would let people take a rest before measuring BP, and 5% said they did not give people time to relax.

In the majority of medical institutions (82.9%), the definition of hypertension was systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg (Table 3). A 56.2% of the medical institutions applied different diagnostic criteria for hypertension according to sex, age, and accompanying diseases. When an examinee has high blood pressure at first visit, the most common strategy is recommendation to revisit after 1 to 2 weeks to measure BP again.

Table 4 is as to which levels of the patient’s BP a doctor decided to treatment. The majority of medical institutions prescribe medication when an examinee has at least above systolic BP of 150 mmHg considering remeasured BP together (Table 4). When the examinee had a systolic BP of 140 mmHg and a diastolic BP of 80 mmHg, 57.1% of medical institutions did not recommend the use of anti-hypertensive medication, and 39.5% of medical institutions recommended medication. When the examinee had a systolic BP of 150 mmHg and a diastolic BP of 95 mmHg, 16.7% of the medical institutions did not recommend the use of anti-hypertensive medication, and 79.5% of medical institutions recommended medication. A total of 171
### Table 1 Physical and human resources related to blood pressure measurement

| Classification                                           | n   | (%)  |
|----------------------------------------------------------|-----|------|
| **Type of medical institution**                          |     |      |
| Clinic                                                   | 154 | (73.3) |
| Hospital                                                 | 38  | (18.1) |
| General hospital                                         | 15  | (7.1)  |
| Long-term care hospital                                  | 2   | (1.0)  |
| Health check-up center                                   | 1   | (0.5)  |
| **Type of sphygmomanometer**                             |     |      |
| Oscilloscope                                             | 109 | (51.9) |
| Mercury                                                  | 44  | (21.0) |
| Aneroid                                                  | 1   | (0.5)  |
| Mercury and oscilloscope                                 | 50  | (23.8) |
| Aneroid and oscilloscope                                 | 5   | (2.4)  |
| Mercury, aneroid and oscilloscope                        | 1   | (0.5)  |
| **Cuff size**                                            |     |      |
| One                                                      | 137 | (65.2) |
| Two                                                      | 66  | (90.4) |
| Three or more                                            | 7   | (9.6)  |
| **Existence of a thermometer**                           |     |      |
| Yes                                                      | 85  | (40.5) |
| No                                                       | 125 | (59.5) |
| **Sphygmomanometer calibration before measurement**      |     |      |
| Yes                                                      | 158 | (75.2) |
| Daily                                                    | 75  | (47.5) |
| Weekly                                                   | 43  | (27.2) |
| Monthly                                                  | 39  | (24.7) |
| No response                                              | 1   | (0.6)  |
| No                                                       | 52  | (24.8) |
| **Place of blood pressure measurement**                  |     |      |
| Open space (e.g. waiting room, reception desk and lobby) | 114 | (54.3) |
| Separate room for measurement of blood pressure          | 60  | (28.6) |
| Separate room for measurements of blood pressure and other examinations | 18  | (8.6)  |
| Open space or separate room                              | 16  | (7.6)  |
| No specified place                                       | 1   | (0.5)  |
| No response                                              | 1   | (0.5)  |
| **Person who measure blood pressure**                    |     |      |
| Nurse                                                    | 130 | (62.0) |
| Physician                                                | 53  | (25.0) |
| Medical technician                                        | 14  | (7.0)  |
| Nurse’s aide                                             | 10  | (5.0)  |
| Administrative staff                                      | 2   | (1.0)  |
| Examinee (automated measurement)                         | 1   | (0.0)  |
medical institutions were considering examinees’ sex, age, and accompanying diseases when they recommended anti-hypertensive medication to examinees. However, the majority of the screening institutions recommended medication, regardless of age, at least 150 mmHg levels of systolic BP.

Discussion

We evaluated the performance of hypertension screening and interpretation of BP measurements in medical institutions performing the national general health screening program in Korea. The JNC-8 and 2013 ESH/ESC as well as Korean Society of Hypertension recommend age-differential BP goal and treatment strategies [11, 17, 19]. The guideline for BP measurement and interpretation in Korea hypertension screening program is no different from these international guidelines.

Diagnosis of hypertension is commonly made from hypertension screening because hypertension has no specific symptoms. Hypertension can be diagnosed by noninvasive BP measurement and controlled by lifestyle changes or drugs, so it is a main target condition of national health screening. The benefits of screening for hypertension have been reported in previous studies. Systematic reviews support the effectiveness of BP screening of adults to detect hypertension and treat them to reduce cardiovascular disease [13]. A population-based cohort study in England reported that reductions in cardiovascular risk factor values were observed in people who regularly received the national health check-up [14]. A retrospective cohort study in Taiwan also reported that nationwide periodic health examinations was effective in promoting early treatment of hypertension, diabetes and hyperlipidemia in adults aged ≥40 years [15].

In Korea, the national health screening program controlled by government in nationwide level was launched in 1980. There are general screening program, national screening program for people at transitional age (44 and 66 years old), cancer screening, and infant screening program. Korea is investing more than 700 billion KRW in the national health examination, and many large private medical institutions are expanding their screening competitively in national screening area [20].

Several previous studies evaluated overall status of the national general health screening program, and suggested some points to be improved [20, 21]. However,
there is no available study which specifically evaluated the performance of BP measurement and interpretation in the national general health screening program in Korea. Screening for hypertension is the most important and cost-effective component of the general health screening, but only limited data are available on specific condition and performance of hypertension screening. As we mentioned above, hypertension can be effectively detected and prevented through measurement of blood pressure, and proper treatment of high blood pressure can prevent cardiovascular events. However, if the quality of BP measurement is poor, interpretation of BP measurement is also not good and proper treatment is not possible. We hope that our report will be used as the baseline data for evaluating and improving the performance of national hypertension screening, because it is the first study on the actual status of BP measurement and interpretation of the national general health screening program.

The current study has some limitations. First, this study was a telephone survey that relies on self-report data and had a relatively small sample size. There is no assurance that the self-reported performance of hypertension screening and interpretation of BP measurements reflect real situation and an aspect of quality control. The self-reported data also may be influenced by the mode of administration of the questionnaire which can affect response rate or response contents [22]. Second, this study included medical institutions only in Seoul and Incheon areas, not in the whole country. Therefore, it may not be appropriate to generalize the present results to the entire. A third limitation is the potential for non-responder bias. It is possible that medical institutions with poor hypertension screening performance are less likely to participate in a telephone survey.

Conclusions
In summary, the medical institutions performing the national general health screening program used mainly oscilloscopic devices for BP measurement, and most of them had measurement manuals and training protocols. Majority of the institutions measured BP multiple times with a resting period, and used the average values to determine an individual’s BP level. However, there is room for improvement in the equipment, environment and quality control procedures for BP measurement of the Korea national general health screening program.

Abbreviations
BP: Blood pressure; KRW: Korean won

Acknowledgements
Not applicable.

Funding
This work was supported by the Research Grant of Korea Centers for Disease Control and Prevention (2015-E33006–00).

Availability of data and materials
The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
SWL contributed to the data collection, analysis and interpretation of the data, and wrote the first draft of the manuscript. HYL, SHL, SHP, THK contributed to the study conceptualization, data interpretation and critical revision of manuscript. HCK contributed to study design, data collection, analysis and interpretation of the data and reviewed a draft of the manuscript and wrote the final manuscript. All authors reviewed the manuscript prior to submission. All authors read and approved the final manuscript.

Table 4 Prescription of anti-hypertensive drugs

|                                      | Yes n (%) | No n (%) | No response n (%) |
|--------------------------------------|-----------|----------|-------------------|
| SBP 140 mmHg, DBP 90 mmHg            | 83 (39.5) | 120 (57.1)| 7 (3.4)           |
| SBP 150 mmHg, DBP 95 mmHg            | 167 (79.5)| 35 (16.7) | 8 (3.8)           |
| SBP 160 mmHg, DBP 100 mmHg           | 184 (87.6)| 18 (8.6)  | 8 (3.8)           |
| SBP 140 mmHg, DBP 80 mmHg            | 47 (22.4) | 154 (73.3)| 9 (4.3)           |
| SBP 160 mmHg, DBP 80 mmHg            | 147 (70.0)| 54 (25.7) | 9 (4.3)           |

When deciding whether to start anti-hypertensive drugs, do you consider the age of the patient?

|                                      | Yes n (%) | No n (%) | No response n (%) |
|--------------------------------------|-----------|----------|-------------------|
| SBP 140 mmHg, DBP 90 mmHg            | 50 (29.2) | 114 (66.7)| 7 (4.1)           |
| SBP 150 mmHg, DBP 95 mmHg            | 133 (77.8)| 31 (18.1) | 7 (4.1)           |
| SBP 160 mmHg, DBP 100 mmHg           | 153 (89.5)| 11 (6.4)  | 7 (4.1)           |
| SBP 140 mmHg, DBP 80 mmHg            | 27 (15.8) | 136 (79.5)| 8 (4.7)           |
| SBP 160 mmHg, DBP 80 mmHg            | 116 (67.8)| 47 (27.5) | 8 (4.7)           |
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Cardiovascular and Metabolic Diseases Etiology Research Center, Yonsei University College of Medicine, Seoul, South Korea. 2Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, South Korea. 3Department of internal medicine, Seoul National University College of Medicine, Seoul, South Korea. 4Division of Cardiology, College of Medicine, Catholic University of Korea, Seoul, South Korea. 5Department of internal medicine, Yonsei University College of Medicine, Seoul, South Korea. 6Graduate School of Public Health, Yonsei University, Seoul, South Korea.

Received: 12 June 2017 Accepted: 11 September 2017
Published online: 05 December 2017

References
1. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557–62.
2. Lee SW, Kim HC, Lee HS, Suh I. Thirty-year trends in mortality from cardiovascular diseases in Korea. Korean Circ J. 2015;45:202–9.
3. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747–57.
4. Feigin VL, Roth GA, Naghavi M, Parmar P, Krishnamurthi R, Chugh S, Mensah GA, Norrving B, Shiue I, Ng M; Global burden of stroke and risk factors in 188 countries, during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet Neurol. 2016;15(9):913-924.
5. Neaton JD, Grimm RH, Paine J, Starn J, Grandits GA, Elmer PJ, Cutler JA, Flack JM, Schoenberger JA, McDonal R. Treatment of mild hypertension study: final results. JAMA. 1993;270:13–24.
6. Dollery C. Hypertension trial results: consensus and conflicts. J Hum Hypertens. 1995;9:403–8.
7. Lewington S. Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (vol 360, pg 1903, 2002). Lancet. 2003;361:1060.
8. Statistics Korea. Statistics for cause of death [Internet]. 2015. Available from: http://kosis.kr. Accessed 9 Apr 2017.
9. Korea Health Statistics. Korea National Health and Nutrition Examination Survey (KNHANES VII). Ministry of Health and Welfare. [Internet]. 2015. Available from: http://kosis.kr. Accessed 2 Oct 2017.
10. Choi KM, Park HS, Han JH, Lee JS, Lee J, Ryu OH, Lee KW, Cho KH, Yoon D, Baik SH. Prevalence of prehypertension and hypertension in a Korean population: Korean National Health and Nutrition Survey 2001. J Hypertens. 2006;24:1515–21.
11. Shin J, Park JB, Kim KI, Kim JH, Yang DH, Pyun WB, Kim YG, Kim GH, Chae SC. 2013 Korean Society of Hypertension guidelines for the management of hypertension: part I-epidemiology and diagnosis of hypertension. Clin Hypertens. 2015;21:1.
12. Medical Service Usage Statistics by Region. 2015. National Health Insurance Corporation. [Internet]. Available from: http://www.nhis.or.kr/bbs7/boards/B0075. Accessed 9 Apr 2017.
13. Sheridan S, Pignone M, Donahue K. Screening for high blood pressure: a review of the evidence for the US Preventive Services Task Force. A m J Prev Med. 2003;25:151–8.
14. Forster AS, Dohia H, Booth H, Dregan A, Fuller F, Miller J, Burgess C, McDermott L, Gulliford MC. Estimating the yield of NHS Health Checks in England: a population-based cohort study. J Public Health. 2015;37:234–40.
15. Lin C-C, Ko C-Y, Liu J-P, Lee Y, Chie W-C. Nationwide periodic health examinations promote early treatment of hypertension, diabetes and hyperlipidemia in adults: experience from Taiwan. Public Health. 2011;125:187–95.
16. National Health Insurance. Health Screening Information [Internet]. Available from: http://sis.nhis.or.kr/site/sis/ggoa. Accessed 14 Aug 2017.
17. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.
18. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560–71.
19. Mancia G, Fagard R, Narkewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 2013;22:193–278.
20. Cho B, Lee CM. Current situation of national health screening systems in Korea. J Korean Med Assoc. 2011;54:666–9.
21. Lee W-C, Lee S-Y. National health screening program of Korea. J Kor Med Assoc. 2010;53:363–70.
22. Bowling A. Mode of questionnaire administration can have serious effects on data quality. J Public Health. 2005;27:281–91.

Submit your next manuscript to BioMed Central and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit